In this model, obeticholic acid and INT-767, two dual GPBAR1 and FXR agonists, as well as the selective GPBAR1 agonist, INT-767, attenuate immune dysfunction-induced fibrosis by multiple mechanisms (112, 113). The gene discussed is GPBAR1; the disease is immune system disorder.